United Cannabis (OTCMKTS:CNAB) VP Tony Verzura sold 12,262 shares of the stock in a transaction on Monday, April 16th. The shares were sold at an average price of $1.24, for a total value of $15,204.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Tony Verzura also recently made the following trade(s):
- On Monday, March 19th, Tony Verzura sold 25,000 shares of United Cannabis stock. The shares were sold at an average price of $1.25, for a total value of $31,250.00.
- On Wednesday, February 14th, Tony Verzura sold 171,865 shares of United Cannabis stock. The shares were sold at an average price of $1.16, for a total value of $199,363.40.
- On Friday, February 9th, Tony Verzura sold 78,763 shares of United Cannabis stock. The stock was sold at an average price of $1.22, for a total value of $96,090.86.
- On Thursday, February 1st, Tony Verzura sold 40,749 shares of United Cannabis stock. The stock was sold at an average price of $1.20, for a total value of $48,898.80.
OTCMKTS:CNAB traded down $0.09 during mid-day trading on Tuesday, reaching $1.14. The company’s stock had a trading volume of 374,768 shares, compared to its average volume of 389,398. United Cannabis has a twelve month low of $0.54 and a twelve month high of $2.50.
TRADEMARK VIOLATION WARNING: “Insider Selling: United Cannabis (CNAB) VP Sells 12,262 Shares of Stock” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://sportsperspectives.com/2018/04/17/insider-selling-united-cannabis-cnab-vp-sells-12262-shares-of-stock.html.
United Cannabis Corporation owns intellectual properties related to growth, production, manufacture, marketing, management, utilization, and distribution of medical marijuana and marijuana infused products in the United States. The company focuses on developing therapeutics, including Prana Bio Nutrient Medicinal products for supplement deficiencies related to the endocannabinoid system, including pain, neuropathy, arthritis, MS, IBS, autism, seizures, eczema, sleep, anxiety, head trauma, opioid dependency, and clinical endocannabinoid deficiencies; and Prana Aromatherapy Transdermal Roll-on line that provides targeted and large surface relief with combinations of aromatherapy.
Receive News & Ratings for United Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.